Table 5.
Efficacy of pamidronate treatment according to genotype
| Parameter | Quantitative (n=5) |
Qualitative (n=6) |
||||
|---|---|---|---|---|---|---|
| Initial | Final | P-value | Initial | Final | P-value | |
| Age at treatment initiation (yr) | 5.2±3.1 | 12.8±10.3 | ||||
| Treatment duration (mo) | 30.6±18.9 | 27.2±14.2 | ||||
| Annual fracture frequency | 1.1±0.9 | 0.9±1.2 | 1.0 | 1.1±0.9 | 0.0±0.0 | 0.027 |
| Height SDS | -1.1±0.7 | -1.0±0.8 | 0.89 | -2.2±1.4 | -2.2±1.4 | 0.786 |
| Lumbar spine BMD z-score | -0.5±1.2 | 0.7±2.6 | 0.279 | -2.7±3.0 | -0.6±3.2 | 0.028 |
| Femoral neck BMD z-score | -2.1±2.1 | -0.5±1.9 | 0.068 | -2.2± 0.8 | -1.5±1.7 | 0.345 |
| Calcium (mg/dL) | 10.0±0.6 | 9.6±0.4 | 0.273 | 9.7±0.6 | 9.4±0.6 | 0.027 |
| Phosphorus (mg/dL) | 5.8±0.9 | 5.1±0.2 | 0.138 | 5.1±0.9 | 4.6±1.0 | 0.058 |
| ALP (IU/L) | 271.0±47.8 | 241.2±59.8 | 0.138 | 225.2±97.4 | 146.7±79.7 | 0.028 |
| PTH (pg/mL) | 24.3±17.6 | 25.4±19.1 | 0.893 | 28.5±21.6 | 29.1±17.2 | 0.463 |
| Osteocalcin (ng/mL) | 82.9±58.5 | 86.5±61.7 | 0.465 | 31.4±30.7 | 19.2±27.0 | 0.068 |
Values are presented as mean±standard deviation.
SDS, standard deviation scores; BMD, bone mineral density; ALP, alkaline phosphatase; PTH, parathyroid hormone.